GLuM8: A Potential Drug Target for Neurological Disorders (G2918)

Target Name: GRM8

NCBI ID: G2918

GRM8

GLuM8: A Potential Drug Target for Neurological Disorders

GluRodase (GRM) is a family of enzymes that catalyze the chemical reaction known as G-protein-coupled receptor (GPCR) signaling. GPCR is a signaling transduction pathway widely present in organisms that plays a crucial role in cellular signaling. Gluronan, the natural product of the GRM enzyme, has been shown to modulate the activity of several GPCRs, including GLUT1, GLUT4, and GLUT5.

The glutamyl hydroxylase (GH) family, which includes GLUT1, GLUT2, and GLUT3, is a subfamily of the GRM enzymes that belong to the N-methyl-D-aspartate (NMA) receptor subfamily. GH enzymes catalyze the N- methylation of the Glu2 residue of specific target proteins, which results in the formation of Glu-4-OH and the depletion of Glu2-OH. This modification is critical for the function of GH enzymes, as it enables them to interact with various signaling molecules , including neurotransmitters and hormones.

GluM8, the latest addition to the GH family, is a potential drug target and biomarker for several neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. The availability of small, highly specific antibodies that can recognize and label GLuM8 has made it an attractive target for researchers studying the role of GLuM8 in disease progression and treatment.

Targeting GLuM8
The GLuM8 gene was identified as a potential candidate for drug targeting in a mouse model of Alzheimer's disease, and subsequent studies have confirmed its involvement in the development and progression of this neurodegenerative disorder. Several studies have shown that GLuM8+ neurons in the hippocampus of Alzheimer's disease patients have reduced levels of GLUT1 and GLUT4, both of which are known to be regulated by GLuM8. Furthermore, immunofluorescence studies have demonstrated that GLuM8+ neurons in the entorhinal cortex, a region of the brain involved in memory and spatial navigation, are predominantly lost in the disease, and that this loss is associated with increased levels of GLUT4-containing neurons.

In addition to its involvement in neurodegenerative diseases, GLuM8 has also been shown to be involved in the development of other psychiatric disorders, including depression and anxiety. Several studies have shown that GLuM8+ neurons in the prefrontal cortex of patients with depression have increased levels of GLUT1 and GLUT4, and that this increase is associated with reduced levels of GLUT2. Similarly, GLuM8 has been shown to be involved in the modulation of anxiety-like behavior in animal models of anxiety disorders.

The potential utility of GLuM8 as a drug target is its ability to modulate the activity of several GPCRs, including GLUT1, GLUT4, and GLUT5. These GPCRs are involved in a wide range of physiological processes, including sensory perception, neurotransmission, and cellular signaling. Therefore, GLuM8 has the potential to intervene on multiple physiological processes and to affect a wide range of cellular and molecular targets.

Methods
To study the GLuM8 protein and its function, researchers have used a variety of techniques, including Western blotting, immunofluorescence, and in vitro assays. Western blotting is a common method used to quantify the levels of GLuM8 protein in cell culture or tissues. Immunofluorescence is a technique that allows researchers to visualize the localization of GLuM8 protein in live cells or tissues. In vitro assays, such as cell-based assays or protein-fragment complementation assays, are used to determine the functional relevance of GLuM8.

Conclusion
In conclusion, GLuM8 is a promising drug target and biomarker for several neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Its involvement in the modulation of GPCRs and its potential to intervene on multiple physiological processes make it an attractive target for research into the mechanisms underlying these disorders. Further studies are needed to determine the full range of GLuM8's functions and its potential as a drug.

Protein Name: Glutamate Metabotropic Receptor 8

Functions: G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity

The "GRM8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GRM8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets